Matricellular protein CCN3 mitigates abdominal aortic aneurysm

Area of Science:

• Vascular Biology
• Matrix Biology
• Cardiovascular Research

Background:

• Abdominal aortic aneurysm (AAA) poses significant health risks, yet its underlying mechanisms remain unclear.
• Extracellular matrix proteins are crucial for maintaining vascular health and function.
• Reduced expression of CCN3 is observed in both animal models and human AAA tissues.

Purpose of the Study:

• To investigate the role of CCN3 in the pathogenesis of abdominal aortic aneurysm.
• To determine if CCN3 levels influence AAA development and progression.
• To explore CCN3 as a potential therapeutic target for AAA.

Main Methods:

• Utilized rodent models of angiotensin II- and elastase-induced AAA.
• Assessed CCN3 expression in murine AAA models and human AAA biopsies.
• Generated Ccn3 knockout and CCN3-overexpressing mice.
• Performed bone marrow transplantation experiments.
• Investigated the involvement of the ERK1/2 pathway.

Main Results:

• Germline deletion of Ccn3 in mice led to severe AAA phenotypes, including elastin fragmentation, inflammation, and cell loss.
• Overexpression of CCN3 protected against AAA formation in mouse models.
• AAA pathology in Ccn3-deficient mice was found to be intrinsic to the vasculature.
• The ERK1/2 pathway was identified as a key regulator in CCN3-dependent AAA development.

Conclusions:

• CCN3 acts as a critical regulator in abdominal aortic aneurysm biology.
• CCN3 deficiency exacerbates AAA development through vascular mechanisms.
• CCN3 represents a promising therapeutic target for preventing and treating vascular disease like AAA.